Pay in 4 interest-free payments of $6.76 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
Cardiovascular Outcomes Trial in Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease Trial 8 [Peptide Innovation for Early Diabetes Treatment (PIONEER 6), NCT02692716] was a multi-center, multi-national, placebo-controlled, double-blind trial
Analyzing data for the 80 percent of participants not taking a GLP-1 allowed the researchers to factor in diabetes severity
The field moved from single GLP-1 receptor agonism, to dual GIP/GLP-1 agonism, and then to adding a third receptor glucagon to capture an energy-expenditure lever on top of appetite and glucose control
Mochi may occasionally send formulations with these additives depending on the pharmacy and prescriber preferences
doi: 10.1038/aps.2013.5, 140 YangX.KawasakiN
